TY - JOUR
T1 - Postoperative radiation rates in stage IIA1 cervical cancer
T2 - Is surgical treatment justified? An Israeli Gynecologic Oncology Group Study
AU - Yagur, Yael
AU - Weitzner, Omer
AU - Gemer, Ofer
AU - Lavie, Ofer
AU - Beller, Uziel
AU - Bruchim, Ilan
AU - Vaknin, Zvi
AU - Levy, Tally
AU - Rabinovich, Alex
AU - Shachar, Inbar Ben
AU - Meirovitz, Amichay
AU - Arie, Alon Ben
AU - Derazne, Estela
AU - Raban, Oded
AU - Eitan, Ram
AU - Kadan, Yfat
AU - Fishman, Ami
AU - Helpman, Limor
N1 - Publisher Copyright:
© 2018
PY - 2018/8
Y1 - 2018/8
N2 - Objectives: Data on the outcome of stage IIA1 cervical cancer is limited, as these tumors comprise a small percentage of early tumors. NCCN guidelines suggest consideration of surgical management for small tumors with vaginal involvement. Our objective was to evaluate the risk of adjuvant radiotherapy in stage IIA1 cervical cancer and its associated features, in order to improve selection of patients for surgical management. Methods: A retrospective cohort study comparing surgically treated cervical cancer patients with stage IB1 and stage IIA1 disease. Women treated between 2000 and 2015 in ten Israeli medical centers were included. Patient and disease features were compared between stages. The relative risk (Fisher's exact test) of receiving post-operative radiation was calculated and compared for each risk factor. A general linear model (GLM) was used for multivariable analysis. Results: 199 patients were included, of whom 21 had stage IIA1 disease. Most features were comparable for stage IB1 and stage IIA1 disease, although patients with vaginal involvement were more likely to have close surgical margins (23.8% vs 8.5%, p = 0.03). Patients with stage IIA1 disease were more likely to receive radiation after surgery (76% vs. 46%, RR = 1.65 (1.24–2.2), p = 0.011). Vaginal involvement as well as depth of stromal invasion, LVSI and lymph node metastases were independent predictors of radiation on multivariable general linear modeling. Conclusions: Cervical cancer patients with vaginal involvement are highly more likely to require postoperative radiation. We recommend careful evaluation of these patients before surgical management is offered.
AB - Objectives: Data on the outcome of stage IIA1 cervical cancer is limited, as these tumors comprise a small percentage of early tumors. NCCN guidelines suggest consideration of surgical management for small tumors with vaginal involvement. Our objective was to evaluate the risk of adjuvant radiotherapy in stage IIA1 cervical cancer and its associated features, in order to improve selection of patients for surgical management. Methods: A retrospective cohort study comparing surgically treated cervical cancer patients with stage IB1 and stage IIA1 disease. Women treated between 2000 and 2015 in ten Israeli medical centers were included. Patient and disease features were compared between stages. The relative risk (Fisher's exact test) of receiving post-operative radiation was calculated and compared for each risk factor. A general linear model (GLM) was used for multivariable analysis. Results: 199 patients were included, of whom 21 had stage IIA1 disease. Most features were comparable for stage IB1 and stage IIA1 disease, although patients with vaginal involvement were more likely to have close surgical margins (23.8% vs 8.5%, p = 0.03). Patients with stage IIA1 disease were more likely to receive radiation after surgery (76% vs. 46%, RR = 1.65 (1.24–2.2), p = 0.011). Vaginal involvement as well as depth of stromal invasion, LVSI and lymph node metastases were independent predictors of radiation on multivariable general linear modeling. Conclusions: Cervical cancer patients with vaginal involvement are highly more likely to require postoperative radiation. We recommend careful evaluation of these patients before surgical management is offered.
KW - Adjuvant chemoradiation
KW - Adjuvant radiation
KW - Cervical cancer
KW - Stage IIA cervical cancer
UR - http://www.scopus.com/inward/record.url?scp=85047496939&partnerID=8YFLogxK
U2 - 10.1016/j.ygyno.2018.05.016
DO - 10.1016/j.ygyno.2018.05.016
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 29807695
AN - SCOPUS:85047496939
SN - 0090-8258
VL - 150
SP - 288
EP - 292
JO - Gynecologic Oncology
JF - Gynecologic Oncology
IS - 2
ER -